{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonic+Dystrophy+Type-1",
    "query": {
      "condition": "Myotonic Dystrophy Type-1"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 26,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonic+Dystrophy+Type-1&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T18:13:39.792Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04886518",
      "title": "Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myotonic Dystrophy 1",
        "Excessive Daytime Sleepiness"
      ],
      "interventions": [
        {
          "name": "Pitolisant Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harmony Biosciences Management, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-06-28",
      "completion_date": "2024-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-07-22T18:13:39.792Z",
      "location_count": 11,
      "location_summary": "Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886518"
    },
    {
      "nct_id": "NCT07630389",
      "title": "Remote Assessments and Genetic Determinants of Congenital and Childhood Myotonic Dystrophy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myotonic Dystrophy Type 1",
        "Congenital DM1",
        "Juvenile DM1",
        "Childhood DM1"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "0 Years to 17 Years"
      },
      "enrollment_count": 100,
      "start_date": "2023-11-13",
      "completion_date": "2030-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-07-22T18:13:39.792Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07630389"
    },
    {
      "nct_id": "NCT06204809",
      "title": "Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myotonic Dystrophy 1"
      ],
      "interventions": [
        {
          "name": "PGN-EDODM1 for infusion",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "PepGen Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-12-12",
      "completion_date": "2025-10-28",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-07-22T18:13:39.792Z",
      "location_count": 7,
      "location_summary": "Irvine, California • Palo Alto, California • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06204809"
    },
    {
      "nct_id": "NCT02251457",
      "title": "Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myotonia Congenita",
        "Paramyotonia Congenita",
        "Myotonic Dystrophy 1"
      ],
      "interventions": [
        {
          "name": "Ranolazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 35,
      "start_date": "2014-08",
      "completion_date": "2017-12-18",
      "has_results": false,
      "last_update_posted_date": "2019-03-05",
      "last_synced_at": "2026-07-22T18:13:39.792Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02251457"
    },
    {
      "nct_id": "NCT05479981",
      "title": "Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "DM1",
        "Muscular Dystrophies",
        "Myotonic Dystrophy",
        "Myotonic Dystrophy 1",
        "Myotonic Disorders",
        "Muscular Disorders, Atrophic",
        "Muscular Diseases",
        "Musculoskeletal Diseases",
        "Neuromuscular Diseases",
        "Nervous System Diseases",
        "Genetic Diseases, Inborn",
        "Heredodegenerative Disorders, Nervous System",
        "Neurodegenerative Diseases"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "AOC 1001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 37,
      "start_date": "2022-08-04",
      "completion_date": "2025-09-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-07-22T18:13:39.792Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05479981"
    },
    {
      "nct_id": "NCT06411288",
      "title": "Global Study of Del-desiran for the Treatment of DM1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "DM1",
        "Myotonic Dystrophy",
        "Myotonic Dystrophy 1",
        "Myotonia",
        "Myotonic Dystrophy Type 1 (DM1)",
        "Dystrophy Myotonic",
        "Myotonic Disorders",
        "Steinert Disease",
        "Steinert",
        "Myotonic Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "AOC 1001 (del-desiran)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 159,
      "start_date": "2024-05-30",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-07-22T18:13:39.792Z",
      "location_count": 18,
      "location_summary": "Stanford, California • Denver, Colorado • Gainesville, Florida + 15 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06411288"
    },
    {
      "nct_id": "NCT02312011",
      "title": "A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myotonic Dystrophy Type 1"
      ],
      "interventions": [
        {
          "name": "IONIS-DMPKRx",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "20 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2014-12",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2022-12-06",
      "last_synced_at": "2026-07-22T18:13:39.792Z",
      "location_count": 8,
      "location_summary": "Stanford, California • Gainesville, Florida • Kansas City, Kansas + 5 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02312011"
    },
    {
      "nct_id": "NCT03959189",
      "title": "Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myotonic Dystrophy, Type 1 (DM1)",
        "Myotonic Dystrophy"
      ],
      "interventions": [
        {
          "name": "ERX-963",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Expansion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2019-06-17",
      "completion_date": "2020-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-23",
      "last_synced_at": "2026-07-22T18:13:39.792Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Miami, Florida • Iowa City, Iowa + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03959189"
    },
    {
      "nct_id": "NCT02308657",
      "title": "Multicenter Observational Study of Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myotonic Dystrophy Type 1"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 120,
      "start_date": "2013-11",
      "completion_date": "2017-10",
      "has_results": false,
      "last_update_posted_date": "2017-10-26",
      "last_synced_at": "2026-07-22T18:13:39.792Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Gainesville, Florida • Kansas City, Kansas + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02308657"
    },
    {
      "nct_id": "NCT05027269",
      "title": "Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "DM1",
        "Myotonic Dystrophy 1",
        "Myotonic Dystrophy",
        "Myotonic Dystrophy Type 1 (DM1)",
        "Dystrophy Myotonic",
        "Myotonic Disorders",
        "Steinert Disease",
        "Myotonic Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "AOC 1001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 39,
      "start_date": "2021-10-28",
      "completion_date": "2023-02-14",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-07-22T18:13:39.792Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05027269"
    }
  ]
}